Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Acquired by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 730,339 shares of the company’s stock after buying an additional 46,119 shares during the period. Lord Abbett & CO. LLC’s holdings in Cellebrite DI were worth $16,089,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in CLBT. State Street Corp raised its holdings in shares of Cellebrite DI by 7.3% in the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after purchasing an additional 30,052 shares in the last quarter. Barclays PLC raised its stake in Cellebrite DI by 29.1% in the third quarter. Barclays PLC now owns 263,657 shares of the company’s stock valued at $4,439,000 after buying an additional 59,395 shares in the last quarter. Tidal Investments LLC lifted its holdings in Cellebrite DI by 59.3% during the 3rd quarter. Tidal Investments LLC now owns 104,478 shares of the company’s stock worth $1,759,000 after buying an additional 38,887 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of Cellebrite DI in the 3rd quarter valued at about $23,402,000. Finally, JPMorgan Chase & Co. raised its position in shares of Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after acquiring an additional 75,092 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

CLBT has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Lake Street Capital lifted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI presently has a consensus rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $19.64 on Friday. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30. The stock has a market cap of $4.70 billion, a P/E ratio of -14.13, a P/E/G ratio of 4.27 and a beta of 1.44. The firm has a fifty day moving average price of $18.73 and a 200 day moving average price of $20.13.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.